ORION-1: A phase 1/2, first-in-human study to assess the safety, tolerability, pharmacokinetics, pharmacodynamics, and antitumor activity of AVZO-023 as a single agent, and in combination with AVZO-021 and/or endocrine therapy in patients with advanced solid tumors
Not yet recruitingCTIS2026-525948-15-00
Avenzo Therapeutics Inc.Advanced Cancer
Target: 28Updated: 2026-10-29